Moshe Szyf, PhD


11_Szyf Headshot_200





Dr. Szyf received his PhD from Hebrew University and did his postdoctoral fellowship in Genetics at Harvard Medical School, joined the department of Pharmacology and Therapeutics at McGill University in Montreal in 1989 and currently holds a James McGill Professorship and GlaxoSmithKline-CIHR Chair in Pharmacology and is a fellow of the Royal Society of Canada. He is the founding co-director of the Sackler Institute for Epigenetics and Psychobiology at McGill and is a Fellow of the Canadian Institute for Advanced Research Experience-based Brain and Biological Development program. Dr. Szyf has been the founder of the first “Pharma” to develop epigenetic pharmacology “Methygene Inc.” and the first journal in epigenetics “Epigenetics.” The Szyf lab has proposed two decades ago that DNA methylation is a prime therapeutic target in cancer and other diseases and has postulated and provided the first set of evidence that the “social environment” early in life can alter DNA methylation launching the emerging field of “social epigenetics.”